DK3387019T3 - Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder - Google Patents

Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder Download PDF

Info

Publication number
DK3387019T3
DK3387019T3 DK16873899.5T DK16873899T DK3387019T3 DK 3387019 T3 DK3387019 T3 DK 3387019T3 DK 16873899 T DK16873899 T DK 16873899T DK 3387019 T3 DK3387019 T3 DK 3387019T3
Authority
DK
Denmark
Prior art keywords
relaxin
methods
proteins
immunoglobulin infusion
immunoglobulin
Prior art date
Application number
DK16873899.5T
Other languages
English (en)
Inventor
Ying Wang
Guangsen Fu
Peter G Schultz
Feng Wang
Yan Liu
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK3387019T3 publication Critical patent/DK3387019T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DK16873899.5T 2015-12-09 2016-12-09 Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder DK3387019T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265344P 2015-12-09 2015-12-09
PCT/US2016/065779 WO2017100540A2 (en) 2015-12-09 2016-12-09 Relaxin immunoglobulin fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
DK3387019T3 true DK3387019T3 (da) 2022-01-10

Family

ID=59013561

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16873899.5T DK3387019T3 (da) 2015-12-09 2016-12-09 Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder

Country Status (6)

Country Link
US (2) US11161891B2 (da)
EP (2) EP4011919A3 (da)
DK (1) DK3387019T3 (da)
ES (1) ES2903257T3 (da)
PT (1) PT3387019T (da)
WO (1) WO2017100540A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3522911B1 (en) 2016-10-07 2021-12-08 Beth Israel Deaconess Medical Center, Inc. Compositions comprising relaxin and methods of use thereof
KR20230146098A (ko) * 2018-05-23 2023-10-18 화이자 인코포레이티드 GUCY2c에 특이적인 항체 및 이의 용도
TW202120536A (zh) * 2019-07-31 2021-06-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
KR20220141315A (ko) * 2020-02-12 2022-10-19 더 스크립스 리서치 인스티튜트 지속성 gm-csf 및 사용 방법

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5911997A (en) 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
AU6777196A (en) 1995-08-15 1997-03-12 Connective Therapeutics Inc. Method of promoting angiogenesis
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
NZ517184A (en) 1999-07-13 2004-02-27 Bolder Biotechnology Inc Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain
ATE474854T1 (de) 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
US6723702B2 (en) 2000-02-09 2004-04-20 Ras Medical, Inc. Use of relaxin treat diseases related to vasoconstriction
AU2012211451A1 (en) 2000-03-01 2012-08-30 Applied Molecular Evolution, Inc. High potency recombinant antibodies and method for producing them
EP2341075A1 (en) * 2000-03-01 2011-07-06 MedImmune, LLC Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
EP2412384A1 (en) 2000-11-28 2012-02-01 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US6740747B2 (en) 2001-04-20 2004-05-25 Azad Kaushik Bovine VDJ cassette, BF1H1, suitable for antigenization
US20080260731A1 (en) 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US20050186526A1 (en) 2002-11-01 2005-08-25 Bas Medical, Inc. Methods and systems for enabling and stabilizing tooth movement
US6984128B2 (en) 2002-11-01 2006-01-10 Bas Medical, Inc. Methods for enabling and stabilizing tooth movement
US7189539B2 (en) 2003-11-25 2007-03-13 Bristol-Myers Squibb Company Polynucleotide encoding a human relaxin receptor, HGPRBMY5v1
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
CA2563433C (en) 2004-04-30 2010-07-13 Bas Medical, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
US20070293485A1 (en) 2006-06-03 2007-12-20 John Lim Drug administration methods
RU2512933C2 (ru) 2008-05-16 2014-04-10 Кортера, Инк. Способ лечения хронической сердечной недостаточности
CN106177914A (zh) 2008-05-16 2016-12-07 科尔泰拉公司 用松弛素治疗与急性心力衰竭相关的呼吸困难
US20100041603A1 (en) 2008-05-16 2010-02-18 Corthera, Inc. Method of Promoting Wound Healing
BRPI0912653A2 (pt) 2008-05-16 2019-09-24 Corthera Inc método de prevenção de parto prematuro
EP2396036B1 (en) 2009-02-13 2017-06-28 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US20120121591A1 (en) 2009-03-20 2012-05-17 Amgen Inc. SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
RU2564900C2 (ru) 2010-03-10 2015-10-10 Дзе Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. Модулирование аквапоринов релаксином
US20110245469A1 (en) 2010-04-02 2011-10-06 Athena Discovery, Inc. Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives
WO2012169822A2 (ko) 2011-06-10 2012-12-13 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
WO2012170977A1 (en) 2011-06-10 2012-12-13 President And Fellows Of Harvard College Modulation of pancreatic beta cell proliferation
AR087020A1 (es) * 2011-07-01 2014-02-05 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos
WO2013007563A1 (en) 2011-07-08 2013-01-17 Bayer Intellectual Property Gmbh Fusion proteins releasing relaxin and uses thereof
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
US10259863B2 (en) 2013-01-11 2019-04-16 The California Institute For Biomedical Research Bovine fusion antibodies
CN112225817A (zh) 2013-07-11 2021-01-15 斯克利普斯研究所 卷曲螺旋免疫球蛋白融合蛋白及其组合物
WO2015188132A1 (en) 2014-06-06 2015-12-10 The California Institute For Biomedical Research Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
WO2018013483A1 (en) 2016-07-11 2018-01-18 The California Institute For Biomedical Research Kv1.3 channel blocking peptides and uses thereof

Also Published As

Publication number Publication date
EP4011919A3 (en) 2022-10-12
PT3387019T (pt) 2022-01-14
WO2017100540A3 (en) 2017-07-20
EP4011919A2 (en) 2022-06-15
ES2903257T3 (es) 2022-03-31
US20190263882A1 (en) 2019-08-29
EP3387019B1 (en) 2021-10-20
WO2017100540A2 (en) 2017-06-15
US20220048969A1 (en) 2022-02-17
EP3387019A4 (en) 2019-04-17
US11161891B2 (en) 2021-11-02
EP3387019A2 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
ZA202004919B (en) Anti-tigit antigen-binding proteins and methods of use thereof
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3356404T3 (da) Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3235830T3 (da) Interleukin-15-proteinkompleks og anvendelse deraf
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
IL246921B (en) Binding proteins and their uses
DK3285777T3 (da) Glycan-terapier og fremgangsmåder til behandling
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3230319T3 (da) Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf
DK3148579T3 (da) Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
DK3209308T3 (da) Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf
DK3240895T3 (da) Sammensætninger og fremgangsmåder til proteinglykosylering
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3498292T3 (da) Uspa2-proteinkonstruktioner og anvendelser deraf
DK3218005T3 (da) Glycan-interagerende forbindelser og anvendelsesfremgangsmåder
DK3551209T3 (da) Insulin-fc-fusioner og fremgangsmåder til anvendelse
DK3099800T3 (da) Ekspression og oprensning af crm197 og beslægtede proteiner
DK3368578T3 (da) Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3100050T3 (da) Immobiliserede proteiner og anvendelse deraf
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse